Reply to Yilmaz and Çetin

Abstract

1. Wenzel SE. Severe adult asthmas: integrating clinical features, biology and therapeutics to improve outcomes. Am J Respir Crit Care Med 2021;203:809–821. 2. GINA. Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. 2019 [accessed 2020 Nov]. Available from: www.ginasthma.org. 3. Stokes JR, Casale TB. Characterization of asthma endotypes: implications for therapy. Ann Allergy Asthma Immunol 2016;117:121–125. 4. Muraro A, Lemanske RF Jr, Hellings PW, Akdis CA, Bieber T, Casale TB, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2016;137:1347–1358. 5. McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med 2019;199:433–445. 6. Santus P, Saad M, Damiani G, Patella V, Radovanovic D. Current and future targeted therapies for severe asthma: managing treatment with biologics based on phenotypes and biomarkers. Pharmacol Res 2019;146:104296. 7. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet 2018;391:783–800.